Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis.
October 1, 2024
This work examines whether there are changes in the self-report of anxiety and depression symptoms in adults with cystic fibrosis (CF) who started taking elexacaftor/tezacaftor/ivacaftor (E/T/I), a new medication that shows great promise in the treatment of CF. The study found that there were no changes in these symptoms in...